GHRH Analog (Entry-Point Research Vial)
Tesamorelin (5mg) will be supplied in Australia by Aussie Peptides with fast domestic shipping to all states and territories.
Tesamorelin is a stabilised analog of growth hormone-releasing hormone (GHRH). Research interest centres on its preferential effect on visceral adipose tissue (VAT) rather than general weight reduction — distinguishing it from GLP-1-class compounds. Mechanism: stimulated endogenous GH release with downstream IGF-1 elevation.
The 5mg vial is the smallest format — suited to short preliminary research studies and first-run testing before stepping up to the 10mg or 20mg vial.
Key Research Areas
Visceral Adipose Reduction — Studied specifically for reducing deep abdominal fat Body Recomposition — Research focused on fat distribution rather than gross weight change GH/IGF-1 Axis — Stimulates endogenous GH release with downstream IGF-1 effects Entry-Point Format — 5mg vial suitable for short preliminary research protocols
Supplied as lyophilized powder at high purity, verified by HPLC and mass spectrometry. 5mg per vial. Fast domestic shipping across Australia.
⚠ For in-vitro research and laboratory use only. Not for human consumption.
⚠ For in-vitro research and laboratory use only. Not intended for human or veterinary use. By purchasing, you confirm you are a qualified researcher and will use this compound in accordance with all applicable laws and regulations.